(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 46.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.68%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.94%.
Ac Immune Sa's revenue in 2025 is $35,701,234.On average, 2 Wall Street analysts forecast ACIU's revenue for 2025 to be $601,458,158, with the lowest ACIU revenue forecast at $456,867,215, and the highest ACIU revenue forecast at $746,049,101. On average, 2 Wall Street analysts forecast ACIU's revenue for 2026 to be $2,805,967,985, with the lowest ACIU revenue forecast at $1,667,816,362, and the highest ACIU revenue forecast at $3,944,119,609.
In 2027, ACIU is forecast to generate $12,514,647,337 in revenue, with the lowest revenue forecast at $11,406,618,827 and the highest revenue forecast at $13,622,675,848.